KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $68.8 million.

  • AbCellera Biologics' Total Current Liabilities fell 1352.81% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year decrease of 1352.81%. This contributed to the annual value of $76.6 million for FY2024, which is 3562.72% down from last year.
  • Per AbCellera Biologics' latest filing, its Total Current Liabilities stood at $68.8 million for Q3 2025, which was down 1352.81% from $67.0 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Total Current Liabilities registered a high of $221.1 million during Q2 2022, and its lowest value of $49.5 million during Q3 2021.
  • In the last 5 years, AbCellera Biologics' Total Current Liabilities had a median value of $89.6 million in 2023 and averaged $103.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 21701.02% in 2022, then plummeted by 5802.09% in 2023.
  • Over the past 5 years, AbCellera Biologics' Total Current Liabilities (Quarter) stood at $120.7 million in 2021, then dropped by 1.95% to $118.3 million in 2022, then grew by 0.59% to $119.0 million in 2023, then plummeted by 35.63% to $76.6 million in 2024, then dropped by 10.19% to $68.8 million in 2025.
  • Its last three reported values are $68.8 million in Q3 2025, $67.0 million for Q2 2025, and $75.4 million during Q1 2025.